Clinical trials
for patients

The objective of the study is to investigate the safety and preliminary antitumor activity of the antibody-drug conjugate OMTX705 (ADC OMTX705 linked to a cytotoxic tubulysin) in patients with advanced or metastatic cancer.

The objective of Part 1 of this clinical trial is to find the best dose of elranatamab when administered in combination with a second drug, daratumumab. In Part 2 of this study, the safety and efficacy of the study drug, elranatamab, will be studied in patients with multiple myeloma who have relapsed or are unresponsive after previous treatment. In this Part 2 of the study, in order to evaluate different administration regimens, participants will be divided into 3 groups: group A, which will rec...

The objectives of this clinical trial are as follows: - To determine the response of patients with CLL/PLLC to treatment with pirtobrutinib (group A) compared to ibrutinib (group B). - To determine the duration of the beneficial effects of treatment with the study drugs (including how long patients live). - To determine safety and tolerability in group A and group B. - To determine how patients in group A fare compared to those in group B.

The objective of this study is to test a new investigational treatment for participants with non-small cell lung cancer.

This study is being conducted to determine: - the safe and tolerable dose of UCART20x22 - the efficacy of UCART20x22 in the treatment of NHLB - how long it takes for the body to eliminate UCART20x22 - how much UCART20x22 reaches the bloodstream This study will also test the safety and effectiveness of different lymphodepletion regimens for patients receiving UCART20x22. Lymphodepletion is a type of therapy that decreases the number of your T cells to make room for the UCART20x22 cells. Three dru...

The purpose of this study is to analyze the levels of the experimental drug ASTX030 in your blood, evaluate the safety and tolerability of the drugs, and find out how participants respond to the drug.